Solventum (NYSE:SOLV) Lowered to “Buy” Rating by Wall Street Zen

Solventum (NYSE:SOLV) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

A number of other analysts have also commented on SOLV. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 price target (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. Argus raised Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a research note on Tuesday, July 1st. Morgan Stanley raised Solventum from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $80.00 to $103.00 in a research note on Tuesday, July 15th. Wells Fargo & Company raised their price target on Solventum from $75.00 to $79.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Finally, KeyCorp began coverage on Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating for the company. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $85.75.

Solventum Trading Down 2.3%

NYSE:SOLV opened at $71.25 on Tuesday. The company has a fifty day moving average of $73.27 and a 200 day moving average of $72.75. Solventum has a 52 week low of $60.70 and a 52 week high of $85.92. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. The firm has a market capitalization of $12.35 billion, a P/E ratio of 32.98, a P/E/G ratio of 2.98 and a beta of 0.53.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. During the same period in the prior year, the business posted $1.56 EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, research analysts predict that Solventum will post 6.58 earnings per share for the current year.

Institutional Trading of Solventum

A number of hedge funds have recently modified their holdings of the business. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Solventum by 0.7% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock valued at $1,500,000 after buying an additional 140 shares in the last quarter. Tradition Wealth Management LLC boosted its holdings in shares of Solventum by 1.6% during the 1st quarter. Tradition Wealth Management LLC now owns 8,830 shares of the company’s stock valued at $671,000 after buying an additional 143 shares in the last quarter. Perigon Wealth Management LLC boosted its holdings in shares of Solventum by 3.8% during the 1st quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company’s stock valued at $331,000 after buying an additional 159 shares in the last quarter. Applied Finance Capital Management LLC boosted its holdings in shares of Solventum by 3.8% during the 2nd quarter. Applied Finance Capital Management LLC now owns 4,428 shares of the company’s stock valued at $336,000 after buying an additional 162 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in shares of Solventum by 1.4% during the 2nd quarter. Lazard Asset Management LLC now owns 11,605 shares of the company’s stock valued at $880,000 after buying an additional 163 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.